Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2025 Issues

A blood management road map in WHO’s latest guidance

August 2025—The World Health Organization released new guidance this spring to provide aid in implementing patient blood management programs and toolkits to support blood health and patient safety at various resource levels. “It’s the job of the clinician to make the right decisions about blood use at the right time. Patient blood management programs help them do that,” says Sherri Ozawa, MSN, RN, a coauthor of the WHO guidance. “What documents like this and others do is help make the bridge between what laboratory professionals already know and changing clinical practice.” Ozawa is director of patient blood management operations for hc1 of Indianapolis, Ind., a company that optimizes laboratory data to improve clinical practice, enabling better patient care, streamlining operations, and reducing costs.

The quest to detect hemolysis in POC blood gas testing

August 2025—Werfen launched in July 2024 its Gem Premier 7000 with iQM3 blood gas testing system. One year in, CAP TODAY publisher Bob McGonnagle spoke with Werfen’s Kristina Powell, Ken Huffenus, and Sofia Afonso for the latest on that and about what Werfen showcased at the ADLM meeting last month.

Cytopathology in focus: Navigating papillary lesions in Lynch syndrome

August 2025—Case summary. A 52-year-old chronic smoker with a known MLH1 mutation and Lynch syndrome presented with a pleural-based lung lesion. Fine-needle aspiration revealed a malignant neoplasm with papillary architecture, featuring enlarged overlapping nuclei, coarse chromatin, prominent nucleoli, and rare mitotic figures. Given the patient’s clinical background and cytologic findings, a broad differential diagnosis including primary and metastatic tumors from both thoracic and ab-dominal origins was considered.

Cytopathology in focus: Small samples, big impact: cytology specimens in the molecular era

August 2025—Strides in medical imaging techniques and procurement methods have led to the acquisition of small diagnostic samples obtained by minimally invasive techniques. Over the same period, the breadth of molecular information that can be derived from limited tumor material has increased exponentially. In the age of targeted cancer therapy, the clinical utility of this information is substantial and, when coupled with the decreasing costs of molecular analysis, the information transformed the treatment landscape of cancer. These advances have brought cytology back into the spotlight as a potential source of material for biomarker analysis.

Cytopathology in focus: What’s new in ’25 head and neck SCC guideline?

August 2025—Human papillomavirus testing has become the standard of care in head and neck squamous cell carcinoma (HNSCC) because of the unique clinical features, staging, and treatment options for HPV-associated HNSCC. HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) exhibits a favorable prognosis and improved response to chemoradiation compared with conventional HNSCC and non-HPV-associated forms, and reporting the HPV status is frequently part of clinical trial enrollments. Many patients with OPSCC present with enlarged level II or III cervical lymph nodes and, as a result, cervical lymph node fine-needle aspiration is often the first, and sometimes only, tissue obtained for diagnostic testing. With a growing menu of options available to test for HPV status, including polymerase chain reaction, DNA in situ hybridization, mRNA ISH, liquid-based HPV assays, and p16 immunohistochemistry, it is not always clear when and which HPV test to use, especially when the diagnosis is made on a cytology specimen.

From the President’s Desk

August 2025—I’ve written in this column many times that pathologists should be leaders of the laboratory. But all of the leadership skills we develop through that role also make us a good fit for many other leadership positions in our health care institutions and beyond. I have met CAP members who are chief medical officers, chief quality officers, presidents of their medical staff, and even CEOs of hospitals and health care networks. The current commander of one of the largest military medical centers in the U.S. is a pathologist.

Clinical pathology selected abstracts

August 2025—The Accreditation Council for Graduate Medical Education (ACGME) oversees graduate medical education and closely monitors resident wellness. In 2017, the ACGME published findings from a national study outlining the causes of death among residents and fellows from 2000 through 2014. The most common overall cause of death was malignant neoplasm, and it was the leading cause of death among female residents and fellows. Suicide was the leading cause of death for male residents and the second leading cause for females. Twenty-three percent of deaths by suicide occurred in the first academic quarter of trainees’ first year in their medical programs.

Anatomic pathology selected abstracts

August 2025—Certain subtypes of colorectal carcinoma pose diagnostic challenges in daily practice due to sometimes overlapping morphologic and immunohistochemical features and are associated with worse prognoses than poorly differentiated adenocarcinoma not otherwise specified (PDA-NOS). Other variants of poorly differentiated colon cancers with solid growth patterns that have, anecdotally, been recognized as posing diagnostic challenges include large cell neuroendocrine carcinoma (LCNEC), medullary carcinoma (MC), undifferentiated carcinoma (UC), and lymphoepithelioma-like carcinoma (LELC). The authors conducted a study to determine survival outcomes between patients with poorly differentiated adenocarcinoma and those with a variant carcinoma morphology that may affect prognosis. They also analyzed interobserver agreement among gastrointestinal pathologists at their institution in subclassifying poorly differentiated colorectal carcinoma. All consecutive patients with diagnoses of PDA-NOS, MC, LCNEC, UC, and LELC between July 2018 and July 2023 were included.

Molecular pathology selected abstracts

August 2025—Childhood malignancies such as Wilms tumor—the most common type of kidney cancer in children—exhibit very few DNA changes when tested by traditional sequencing methods. Some of these types of tumors have fewer genetic anomalies than age-matched normal tissue. This raises the question, How can such genetically “quiet” malignancies emerge and progress without conventional driver mutations? To address this question, the authors employed high-resolution, ultra-deep sequencing to determine if hypomutation in juvenile kidney cancers characterized by a paucity of mutations, specifically Wilms tumor, is genuine or an artifact of conventional analytical constraints. By applying high-resolution duplex sequencing (Nanoseq) to Wilms tumors and matched normal kidneys from six pediatric patients, including four infants and two school-age children, the authors showed that standard bulk whole genome sequencing significantly underestimates the mutational burden in tumors from infants.

Newsbytes

August 2025—Recognizing the value of researching options before purchasing a big-ticket item, the College of American Pathologists has developed the AI Playground to help pathologists assess artificial intelligence tools before going all-in on a technology that may not end up suiting their needs, among other potential issues. The playground will offer cutting-edge AI tools that pathologists can test-drive from the comfort of their own laboratories using simulated data sets on a platform designed specifically for that purpose. It will be available to CAP members at no charge and accessible via the CAP website after it is debuted in the CAP Innovation Hub and the College’s booth at CAP25, in Orlando, next month.

MARKETPLACE

TRENDING